These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28063177)

  • 1. Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.
    Gow CH; Chang HT; Lim CK; Liu CY; Chen JS; Shih JY
    Genes Chromosomes Cancer; 2017 May; 56(5):373-381. PubMed ID: 28063177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Gow CH; Hsieh MS; Wu SG; Shih JY
    Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
    Wang Y; Zhang S; Wu F; Zhao J; Li X; Zhao C; Ren S; Zhou C
    BMC Cancer; 2018 Mar; 18(1):326. PubMed ID: 29587667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
    D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
    J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
    Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
    Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
    Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
    Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations.
    Kriegsmann M; Harms A; Kazdal D; Fischer S; Stenzinger A; Leichsenring J; Penzel R; Longuespée R; Kriegsmann K; Muley T; Safi S; Warth A
    Pathol Res Pract; 2018 Mar; 214(3):408-416. PubMed ID: 29487011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
    Yang JC; Wu YL; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu CP; O'Byrne K; Feng J; Lu S; Huang Y; Geater SL; Lee KY; Tsai CM; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su WC; Lee KH; Kato T; Massey D; Shahidi M; Zazulina V; Sequist LV
    Lancet Oncol; 2015 Feb; 16(2):141-51. PubMed ID: 25589191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
    Wang Y; Li RQ; Ai YQ; Zhang J; Zhao PZ; Li YF; He WJ; Xia YX; Li WH
    Clin Transl Oncol; 2015 Sep; 17(9):727-36. PubMed ID: 26041721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
    Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
    Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.
    Li C; Fang R; Sun Y; Han X; Li F; Gao B; Iafrate AJ; Liu XY; Pao W; Chen H; Ji H
    PLoS One; 2011; 6(11):e28204. PubMed ID: 22140546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
    Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
    Oh IJ; Hur JY; Park CK; Kim YC; Kim SJ; Lee MK; Kim HJ; Lee KY; Lee JC; Choi CM
    Clin Lung Cancer; 2018 Sep; 19(5):e775-e781. PubMed ID: 30149884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.
    Rotella V; Fornaro L; Vasile E; Tibaldi C; Boldrini L; Chella A; D'Incecco A; Cirigliano G; Chioni A; Lupi C; Sensi E; Ginocchi L; Giovannelli S; Pennucci MC; Fontanini G; Baldini E
    J Exp Clin Cancer Res; 2014 Oct; 33(1):77. PubMed ID: 25300933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.